Stephanie R Hatfield, MD | |
113 Port Ln, Gilbertsville, KY 42044-8700 | |
(270) 362-8257 | |
(270) 362-2259 |
Full Name | Stephanie R Hatfield |
---|---|
Gender | Female |
Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
Location | 113 Port Ln, Gilbertsville, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023004785 | NPI | - | NPPES |
64184245 | Medicaid | KY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 18424 (Kentucky) | Primary |
282N00000X | General Acute Care Hospital | 18424 (Kentucky) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Stephanie R Hatfield, MD 113 Port Ln, Gilbertsville, KY 42044-8700 Ph: (270) 362-8257 | Stephanie R Hatfield, MD 113 Port Ln, Gilbertsville, KY 42044-8700 Ph: (270) 362-8257 |
News Archive
New research published on the preprint server bioRxiv* performed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic simulations to understand the evolutionary transition from a bat-adapted SARS-CoV-2 to a human-adapted virus.
Two identical cigarettes led to a discovery by scientists at the Virginia Tech Carilion Research Institute. Study participants inhaled nicotine, yet they showed significantly different brain activity. Why the difference? Some subjects were told their cigarettes were nicotine free.
pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.
A ground breaking computer game developed by a University of Salford lecturer to help educate young South Africans about the dangers of HIV and AIDS will be piloted in July.
Researchers at Baylor College of Medicine and Roche NimbleGen Inc., a fully integrated part of Roche Applied Science, have published details of a highly efficient and cost-effective method for capturing targeted regions of the genome via NimbleChip microarrays in preparation for high-throughput 454 Sequencing.
› Verified 7 days ago